Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nilotinib versus imatinib as first-line therapy for unresectable or metastatic GIST
NL-OMON35647Phase 3Active, not recruiting
- Sponsor
- Novartis
- Start
- Aug 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in gastrointestinal stromal tumor (GIST) comparing Nilotinib with Imatinib (2 arms). Primary endpoint: Progression-free survival. Started Aug 2009; status: active, not recruiting.
02
Drugs
nilotinibimatinib
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on NL-OMON35647.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON35647.